NCT06340958 - A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

June 6, 2025

Study Completion Date

January 10, 2026

Conditions

Adjunctive Treatment of Major Depressive Disorder (MDD)

Interventions

DRUG

CLE-100

1 tablet of CLE-100 administered once daily

DRUG

Placebo

1 tablet of placebo administered once daily

Trial Locations (23)

20877

Clinical Site 108, Gaithersburg

30030

Clinical Site 118, Atlanta

30060

Clinical Site 138, Marietta

31405

Clinical Site 114, Savannah

32502

Clinical Site 132, Pensacola

33024

Clinical Site 102, Hollywood

33166

Clinical Site 140, Miami Springs

33319

Clinical Site 105, Lauderhill

39232

Clinical Site 116, Flowood

44236

Clinical Site 103, Beachwood

44720

Clinical Site 119, North Canton

60123

Clinical Site 120, Elgin

60640

Clinical Site 127, Chicago

63368

Clinical Site 126, O'Fallon

73112

Clinical Site 135, Oklahoma City

75093

Clinical Site 137, Plano

78737

Clinical Site 107, Austin

84107

Clinical Site 117, Murray

91786

Clinical Site 130, Upland

92037

Clinical Site 139, La Jolla

94549

Clinical Site 131, Lafayette

98007

Clinical Site 115, Bellevue

08755

Clinical Site 101, Toms River